首页> 外文OA文献 >Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer

【2h】

Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer

机译：从电子健康记录数据产生现实世界肿瘤负担终点：再次入学，放射学 - 锚定和临床医生锚定的方法，用于抽象非小细胞肺癌的现实世界进展

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Sandra D. Griffith; Melisa Tucker; Bryan Bowser; Geoffrey Calkins; Che-hsu (Joe) Chang; Ellie Guardino; Sean Khozin; Josh Kraut; Rebecca Miksad; Paul You; Deb Schrag; Amy P. Abernethy;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer [J] . Griffith Sandra D., Tucker Melisa, Bowser Bryan, Advances in therapy. . 2019,第8期

机译：从电子健康记录数据产生现实世界肿瘤负担的终点：再次入学，放射学 - 锚定和临床医生锚定的方法，用于抽象非小细胞肺癌的现实世界进展
2. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort [J] . Giulio Metro, Alfredo Addeo, Diego Signorelli, Journal of Thoracic Disease . 2019,第12期

机译：拯救化疗或Pembrolizumab的结果超出了具有或没有局部消融治疗的晚期非小细胞肺癌，PD-L1≥50％在一线免疫疗法进展：来自欧洲队列的现实世界数据
3. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. [J] . Nishino M, Jackman DM, Hatabu H, AJR: American Journal of Roentgenology : Including Diagnostic Radiology, Radiation Oncology, Nuclear Medicine, Ultrasonography and Related Basic Sciences . 2010,第3期

机译：晚期非小细胞肺癌新的实体瘤反应评估标准（RECIST）指南：与原始RECIST的比较及其对靶向治疗肿瘤反应评估的影响。
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The Role of Metformin on Non-Small Cell Lung Cancer Progression and Skeletal Muscle Health [D] . Bond, Nicole Lynn-Stott. 2021

机译：二甲双胍对非小细胞肺癌进展和骨骼肌健康的作用
6. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50 who progress on first-line immunotherapy: real-world data from a European cohort [O] . Giulio Metro, Alfredo Addeo, Diego Signorelli, 2019

机译：一线免疫治疗进展的PD-L1≥50％的晚期非小细胞肺癌的挽救性化疗或pembrolizumab的进展超过有无局部消融疗法的进展是否进展为一线免疫疗法
7. Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC) [O] . X. Ma, N.C. Nussbaum, K. Magee, 2019

机译：高级非小细胞肺癌（ANSCLC）患者的真实世界响应率（RWRR）对重复性的响应率的比较

Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer

著录项

引文网络

相似文献

相关主题

期刊订阅